It has been shown that HSP90 is a potential target in MYC-driven medulloblastomas, where treatment with an HSP90 inhibitor Onalespib significantly reduced the growth of those tumors and prolonged the survival in mice.47 Its upregulation in later clones in our tumor datasets further indicates its importance for the progression of human MYC-driven tumors and suggests its relevance as a therapeutic target. The gene discussed is MYC; the disease is medulloblastoma.